105 related articles for article (PubMed ID: 7534858)
21. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
22. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
23. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
Novitsky V; Wester CW; DeGruttola V; Bussmann H; Gaseitsiwe S; Thomas A; Moyo S; Musonda R; Van Widenfelt E; Marlink RG; Essex M
AIDS Res Hum Retroviruses; 2007 Jul; 23(7):868-78. PubMed ID: 17678469
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
25. In vitro assays show a dissociation of reverse transcriptase activity and core antigen (p24) production in two HIV-1 isolates from a patient receiving long-term treatment with zidovudine (ZDV).
Masquelier B; Combeau T; Poveda JD; Delord B; Pellegrin JL; Sallafranque-Andreola ML; Tarrago-Litvak L; Fleury HJ
J Acquir Immune Defic Syndr (1988); 1991; 4(5):499-505. PubMed ID: 1707962
[TBL] [Abstract][Full Text] [Related]
26. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
27. Characterization of HIV isolates arising after prolonged zidovudine therapy.
Mayers DL; McCutchan FE; Sanders-Buell EE; Merritt LI; Dilworth S; Fowler AK; Marks CA; Ruiz NM; Richman DD; Roberts CR
J Acquir Immune Defic Syndr (1988); 1992; 5(8):749-59. PubMed ID: 1381438
[TBL] [Abstract][Full Text] [Related]
28. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
29. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
[TBL] [Abstract][Full Text] [Related]
30. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.
Eastman PS; Urdea M; Besemer D; Stempien M; Kolberg J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):264-73. PubMed ID: 7540490
[TBL] [Abstract][Full Text] [Related]
31. Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients.
Cleland A; Watson HG; Robertson P; Ludlam CA; Brown AJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):6-18. PubMed ID: 8624762
[TBL] [Abstract][Full Text] [Related]
32. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA.
Kaye S; Comber E; Tenant-Flowers M; Loveday C
AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1221-5. PubMed ID: 8573378
[TBL] [Abstract][Full Text] [Related]
33. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
34. Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
Bélec L; Legoff J; Si-Mohamed A; Andréoletti L; Mbopi-Kéou FX; Kolberg J; Matta M; Detmer J; Piketty C; Kazatchkine MD
J Med Virol; 2002 Sep; 68(1):1-6. PubMed ID: 12210423
[TBL] [Abstract][Full Text] [Related]
35. Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy.
Andreoni M; Sarmati L; Nicastri E; Ventura L; Ercoli L; Parisi SG; Giannini G; Galluzzo C; Vella S
J Med Virol; 1998 Dec; 56(4):332-6. PubMed ID: 9829638
[TBL] [Abstract][Full Text] [Related]
36. Additional mutations detected in sequential HIV-1 isolates from ZDV-treated patients.
Magierowska-Jung M; Agut H; Katlama C; Autran B; Huraux JM
J Med Virol; 1997 Jan; 51(1):48-55. PubMed ID: 8986949
[TBL] [Abstract][Full Text] [Related]
37. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
[TBL] [Abstract][Full Text] [Related]
38. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
[TBL] [Abstract][Full Text] [Related]
39. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
40. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
